The Nasdaq staged a more than 2 percent rally back from the brink of correction territory Tuesday in the biggest one day turnaround in five years.» Read More
Talk about a tempestuous affair. It looks like investors are again falling for stocks that they scorned just days ago.
After a rough patch last week where investors sold some of the market's hottest stocks, momentum names led a sharp rally in the Nasdaq on Tuesday.
The big issue for this quarter will be: will they economy pick up? The big debate for this quarter will be growth versus value.
Price action has led Jim Cramer to question whether 3 powerful themes have started to sputter out.
Currently sellers are going after the stocks of companies with excellent long-term prospects. Huh?
Stocks wrapped up the session on a high note, with the Dow logging triple-digit gains, after Federal Reserve Chair Janet Yellen said there's still room for the central bank to help the economy. But major index ended relatively flat for the first quarter.
Why do some drugs, like Gilead's Sovaldi, cost more in the U.S. than in other countries. Shelia Dharmarajian reports for "Nightly Business Report."
March 29- Gilead Sciences Inc, under fire for pricing a new hepatitis C drug at $1,000 a pill, has discount agreements with a number of health insurers, a company executive said in an interview.
*Momentum stocks still in focus; Netflix falls. NEW YORK, March 28- U.S. stocks ended up on Friday but off their session highs as a late afternoon selloff in the biotechnology sector weighed on the overall market. The Nasdaq Composite Index fell nearly 3 percent for the week, marking its worst week since October 2012.
Biotech has been so hot the past two years that the sector is starting to raise red flags.
Some of Friday's midday movers:
The "Fast Money" traders share their final trades of the day.
*Facebook buys Oculus for $2 billion. NEW YORK, March 26- U.S. stocks rose on Wednesday as geopolitical tensions over Ukraine appeared to ease and the latest U.S. economic data pointed to improving conditions. Russia and the West drew a tentative line under the Ukraine crisis after U.S.
There’s a vicious new trend underway in the market and Cramer says stocks of perfectly good companies could take a big hit.
So-called momentum stocks were still down for the day but off their lows, including Netflix, down 2.1 percent at $370.84. Netflix has declined for 14 of the past 15 sessions, falling almost 19 percent over that stretch.
NEW YORK, March 25- U.S. stocks rose by late afternoon on Tuesday in a volatile session, rebounding from a two-day decline as a strong read on consumer confidence increased optimism about the economy. By about 3 p.m., the index was down only 0.2 percent after moving quickly in and out of positive territory.
Jim Cramer on Tuesday names four stocks that could signal whether the Nasdaq could continue to climb.
A high-priced drug sold by Gilead Sciences is under lawmakers' scrutiny. But one analyst says there's a bigger problem.
Some of Tuesday's midday movers:
Biogen CEO George Scangos talks about future growth opportunities at the company on CNBC's "Fast Money."